Cell Therapeutics Inc (NASDAQ:CTIC) signs agreement with Baxter International


Dallas, Texas 11/18/2013 (Financialstrend) – Last week, Cell Therapeutics Inc (NASDAQ:CTIC) and Baxter International jointly announced that they have inked an exclusive global licensing-agreement via which they will develop & commercialize pacritinib. Pacritinib is the novel investigational JAK2/FLT3-inhibitor that has activity against genetic-mutations that are linked to leukemia, myelofibrosis and some solid tumors. Currently, it is in Phase-III development for patients suffering from myelofibrosis, a chronic malignant-bone marrow disorder.

Under the agreement terms, Baxter will gain exclusive-commercialization rights for all the indications for pacritinib outside the U.S & Cell Therapeutics Inc (NASDAQ:CTIC) and Baxter will jointly-commercialize pacritinib within the U.S. Baxter will make an up-front payment of $60M to the latter. This includes an equity-investment in CTI of $30 M. In addition to this, Cell Therapeutics Inc (NASDAQ:CTIC) is eligible to also receive clinical & regulatory as well as commercial-launch milestone payments of upto $112M. Of these, $40M is related to clinical-milestones.

Friday’s trading

In Friday’s trading session, Cell Therapeutics Inc (NASDAQ:CTIC) rose by 6.86%. The shares opened at a price of $1.96, which touched the intraday high of $2.17 and headed to a close of $1.87. Around 34.50 million exchanged hands over the trading day and an average volume of 3.70 million shares were traded over a 30 day period. The 52-week low of Cell Therapeutics Inc (NASDAQ:CTIC) shares is $0.97 and its 52-week high is $2.17. The company has a market capitalization of $214.63 million.                                        

About the company

Cell Therapeutics Inc (NASDAQ:CTIC) is a bio- pharmaceutical company that focuses on acquiring, development & commercialization of less-toxic ways to treat cancer. It is focusing its efforts on the treatments that target different blood-related cancers in which there are unmet medical needs. Cell Therapeutics Inc (NASDAQ:CTIC) is mainly focused on the commercialization of PIXUVRI in the European Union for multiple- relapsed/ refractory-aggressive non-Hodgkin lymphoma & is conducting a Phase-III clinical-trial of pacritinib in the treatment of myelofibrosis. 

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.